US FDA authorizes Pfizer’s coronavirus vaccine for emergency use
|The US Food and Drug Administration (FDA) announced the much-awaited authorization of Pfizer and BioNTech's jointly developed coronavirus vaccine for emergency use (EUA) late Friday.
This comes after the vaccine advisers to the US medical regulator voted 17 to 4 Thursday, recommending the approval of the vaccine for emergency use.
Pfizer’s covid vaccine, which has shown 95% efficacy in a late-stage trial, will be available for the first inoculations early next week. Canada also authorized the vaccine and expects to start inoculations next week.
Additional details
“The FDA said the vaccine can be given to people aged 16 and older.”
“Healthcare workers and elderly people in long-term care facilities are expected to be the main recipients of the first round of 2.9 million doses.”
In response to the FDA authorization, US President Donald Trump posted a video on Twitter, citing, “the first vaccine will be administered in less than 24 hours.”
— Donald J. Trump (@realDonaldTrump) December 12, 2020
— Donald J. Trump (@realDonaldTrump) December 12, 2020
— Donald J. Trump (@realDonaldTrump) December 12, 2020
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.